Zydus Lifesciences receives final approval from the US FDA for Sucralfate Tablets USP, 1 gram

The United States Food and Drug Administration (USFDA) has given final approval to Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) to produce and market Sucralfate Tablets USP, 1 gramme (USRLD: Carafate Tablets, 1 gramme). By creating a protective coating over ulcers and preventing further damage, sucralfate is used to treat and prevent ulcers in the intestines. Ulcers heal more quickly as a result. The topical manufacturing facility of the group in SEZ, Ahmedabad (India), will produce the medication.